Protocol Ledger

NCT04963296 · Phase III · ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

Interventional Phase III clinical trial protocol NCT04963296 sponsored by Roche / Genentech in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-10-26 Enrollment: 303 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04963296
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)303 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04963296
Protocol FieldVerified Registry Value
NCT IdentifierNCT04963296
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment303 participants (ACTUAL)
Registered Start Date2021-10-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04963296
Hospital Research SiteLocationSite Profile
Providence Medical FoundationFullerton, CAOpen Hospital Dossier ->
Columbia University Irving Medical CenterNew York, NYOpen Hospital Dossier ->
Ohio State University Comprehensive Cancer CenterColumbus, OHOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI